Company intelligence / Profile preview
MindMed
New York City, New York, United Statesmindmed.co ↗
- Ownership
- Public · MNMD
- Development stage
- Phase 2
01
Overview
MindMed is advancing a pipeline of novel product candidates targeting brain health disorders. Its lead program, MM120 ODT (lysergide D-tartrate), is in Phase 3 trials for generalized anxiety disorder and preparing for Phase 3 in major depressive disorder. Early clinical data show statistically significant improvements in GAD scores. Another candidate, MM402 ((R)-(-)-MDMA), is in Phase 1 trials for autism spectrum disorder.
- Therapeutic areas
- Psychiatry
- Modalities
- Small moleculePsychedelic compoundPsychoplastogen
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
03
Partnerships
None publicly disclosed with major pharma as of June 2025.
Beyond the preview
Go deeper on MindMed.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MindMed.